Menu

Events & Webinars

Subcutaneous Insulin Use in Adults: Addressing Risks and Optimizing Safety

 
A midday symposium conducted at the 2017 ASHP Midyear Clinical Meeting and Exhibition

Wednesday, December 6, 2017 - 11:30am-1:00pm ET
Room W103, Level 1 – Orange County Convention Center-West Concourse

 

Register to attend in Orlando
 

Overview

Insulin therapy, while essential to the health of millions of patients, continues to be a leading cause of serious patient harm when used in error. This symposium will provide up-to-date information on the top insulin safety issues facing practitioners and an overview of ISMP’s newly-released national guidelines for safe subcutaneous insulin use. Expert speakers will discuss some of the unique challenges involved in managing complex insulin therapy across the continuum of care, including the use of concentrated insulins, insulin vials, and pens.

Objectives

The target audience for this activity includes pharmacists and pharmacy technicians in health-system settings. At the completion of this symposium, the participant will be able to:

  • Describe the risks associated with subcutaneous insulin that have led to errors, as well as other preventable adverse outcomes associated with insulin management across the continuum of care.
  • Compare your organization’s efforts to prevent subcutaneous insulin errors to ISMP’s Safe Practice Guidelines for Subcutaneous Insulin Use in Adults.
  • Discuss three common practice concerns and reality-based solutions with insulin management across the continuum of care.
  • Identify unique survival skills practitioners can teach all patients regarding subcutaneous insulin therapy.

Agenda

10:45am - Doors open
11:30am-1:00pm - Symposium
 
Space is limited and pre-registration is encouraged. Pre-registration is for planning purposes only and seating will be available on a first-come, first-served basis.

Food and beverages are not provided at Midday Symposia. This ASHP policy considers the varied internal policies of commercial supporters related to the Physician Payments Sunshine Act. You are welcome to bring your lunch to the session.

Topics and Faculty

Introduction and Overview
Michael R. Cohen, RPh, MS, ScD (hon), DPS (hon), FASHP
President, ISMP

Complicated and Complex: Will Subcutaneous Insulin Use Ever Be Safe?
Matthew Grissinger, RPh, FISMP, FASCP
Director of Error Reporting Programs, ISMP

Recommended Subcutaneous Insulin Safe Practice Guidelines from the ISMP National Summit
Susan Paparella, MSN, RN
Vice President, ISMP

Insulin Safety: It Takes a Village
Jane Jeffrie Seley, DNP, MSN, MPH, GNP, BC-ADM, CDE, CDTC, FAADE, FAAN
Nurse Practitioner & Program Manager, Inpatient Glycemic Control Program,
Weill Cornell Division of Endocrinology, Diabetes & Metabolism, New York-Presbyterian Hospital, New York, NY

CE Accreditation

Pharmacists and Pharmacy Technicians

This CE activity is jointly provided by ProCE, Inc. and the Institute for Safe Medication Practices (ISMP). ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-17-413-L05-P/T has been assigned to this knowledge-based live CE activity (initial release date December 6, 2017). This CE activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Successful completion of the online post-test and evaluation at www.ProCE.com no later than January 5, 2018 is required to receive CE credit. CE credit will be automatically uploaded to NABP/CPE Monitor upon completion of the post-test and evaluation. No partial credit will be given.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Conflict of interest disclosures are required of all faculty and shall be provided to all participants at the conference.

Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.

Funding

This symposium is funded through an educational grant from Lilly and Novo Nordisk.

    

Register to attend in Orlando
 

Institute for Safe Medication Practices (ISMP)
200 Lakeside Drive, Suite 200, Horsham, PA 19044
Phone: (215) 947-7797 www.ismp.org